BSE filing, NSE: AARTIPHARM. Summary written from the filing by ALFA Finder's alert engine.
Aarti Pharmalabs Ltd: key numbers
- Share price
- ₹879.00
- Market cap
- ₹7,971 Cr
- Revenue (annual)
- ₹1,819 Cr
- Net profit (annual)
- ₹174.7 Cr
- P/E (TTM)
- 37.4×Sector 46.5×
- Promoter holding
- 39.66%-3.20% QoQ
- FII holding
- 8.16%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aarti Pharmalabs Ltd
All →Aarti Pharmalabs Q2 FY27 Results: Net Profit ₹71.5 Cr, Up 248.8% YoY
Aarti Pharmalabs Ltd reported revenue from operations of ₹610.5 Cr (+45.9% YoY) and net profit of ₹71.5 Cr (+248.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹71.5 Cr · +248.8% YoY
Aarti Pharmalabs Employee Stock Options
Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Aarti Pharmalabs Board Meeting Date
Aarti Pharmalabs Ltd has scheduled a board meeting for October 28, 2026, to consider and approve unaudited standalone and consolidated financial results.
Aarti Pharmalabs Legal & Regulatory
Aarti Pharmalabs has filed a Writ Petition with the Gujarat High Court challenging a ₹59.50 Crore stamp duty and penalty order from the Superintendent of Stamps.
- Value
- ₹59.50 Cr
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs Limited has reconstituted its Nomination and Remuneration Committee effective October 01, 2026. Smt. Jeenal Savla will serve as the Chairperson of the committee.
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.
Avience Biomedicals Other Announcement
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.